Journal of Clinical Oncology
Articles in this Issue
Five-year survival outcomes in NSCLC patients with concurrent GERD on proton pump inhibitors receiving pembrolizumab or nivolumab: A global study.
e20611 Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment of non-small cell lung cancer (NSCLC), though response variability r...
Chemotherapy (CT) declination among patients with early-stage hormone receptor positive breast cancer (BC) and high Oncotype DX recurrence scores (RS).
525 Background: Among patients with hormone receptor positive, HER2-negative (HR+/HER2-) BC, the 21-gene Oncotype DX assay is both prognostic of recurrenc...
Impact of proton pump inhibitor (PPI) pharmacogenomics (PGx) on toxicities associated with immune checkpoint inhibitor (ICI) therapy.
12128 Background: There is evidence for the impact of PPIs on clinical outcomes when given concurrently with ICI therapies. Moreover, CYP2C19 genotype imp...
Efficacy and safety of neoadjuvant TQB2102 in women with locally advanced or early HER2-positive breast cancer: A randomized, open-label, multi-centre phase 2 trial.
591 Background: Standard neoadjuvant regimens for HER2-positive breast cancer include trastuzumab and pertuzumab combined with chemotherapy, and the effic...
Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis.
7551 Background: MRD is a measure of response in the bone marrow (BM) but is limited by patchy infiltration of BM plasma cells and lack of plasmacytoma as...
Genomic landscape and biomarker analyses utilizing circulating-tumor DNA in advanced esophageal squamous cell carcinoma: Sub-analysis of SCRUM-MONSTAR GOZILA.
4024 Background: Advanced esophageal squamous cell carcinoma (ESCC) is a cancer type with a poor prognosis, with limited survival benefits from current mu...
Deep learning algorithm for accurate diagnosis of oral cancer and precancers.
e18135 Background: Oral cancer (OC) caused approximately 178,000 deaths in 2020 globally, often due to late stage diagnosis and poor survival rates. A pro...
Prevalence of androgen receptor ligand-binding domain mutations (AR-LBDm) in circulating tumor DNA (ctDNA) versus tissue biopsies in participants (pts) with metastatic castration-resistant prostate cancer (mCRPC) and other tumor types.
3049 Background: AR-LBDm is a common mechanism of resistance to AR-directed therapies in patients with mCRPC. However, data on the utility of ctDNA-based...
Dupilumab for bullous pemphigoid induced by immune checkpoint inhibitors.
e24110 Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are associated with treatment-limiting immune-related cutane...
Analysis of conflicts of interest in clinical trials published in JCO: A large language model-assisted longitudinal study.
e23042 Background: Conflicts of interest (COIs) in oncology trials, particularly those arising from industry funding and author affiliations, may influenc...
Preliminary analysis of disitamab vedotin combined therapy for HER2-expressing platinum-sensitive recurrent ovarian/peritoneal/fallopian tube cancer (Diversity study): A single-arm, multicenter phase II trial.
5564 Background: Platinum-sensitive recurrent epithelial ovarian/peritoneal/fallopian tube cancer (PSROC) patients often exhibit reduced responsiveness to...
National trends in disability-adjusted life years (DALYs) of gastric cancer among elderly (70+ years) from 1990-2021: A global burden of disease study.
e16456 Background: Gastric cancer is one of the significant contributors of mortality and morbidity, especially in older patients. Analyzing national tren...
Combining machine learning with the immunohistochemical expression of AMBRA1 and loricrin to identify non-ulcerated AJCC stage I/II melanomas at high-risk of metastasis.
9570 Background: Precision-based personalised biomarkers able to identify both low-risk and high-risk patient subpopulations with localised cutaneous mela...
A phase 1/2 study of KSQ-004EX: Autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and Regnase-1, in patients with select advanced solid tumors.
TPS2675 Background: The effectiveness and durability of TIL therapy may be limited by the immunosuppressive tumor microenvironment and baseline functional...
Dosing tolerability and adverse events (AEs) in dihydropyrimidine dehydrogenase ( <i>DPYD</i> ) variant carriers receiving genotyping-guided fluoropyrimidine (FP) dosing.
3095 Background: We previously showed that DPYD genotype-guided FP (5-FU, capecitabine) dosing reduces severe AEs and hospitalizat...
The incidence and therapeutic regimen altering effects of immune checkpoint inhibitor–associated peripheral edema: A systematic review and meta-analysis.
e14601 Background: Immune checkpoint inhibitors (ICIs) provide a long-term survival benefit across multiple cancer types, however immune-related adverse e...
AI immuno-profiling: Predicting T and B cells directly from H&E-stained slides.
e13592 Background: Tumor-infiltrating immune cells, especially T (CD3+) and B (CD20+) lymphocytes, are important prognostic and predictive biomarkers in o...
Outcomes of germline expedited point of care (POC) genetic testing through telehealth in the Veterans Health Administration (VA).
1655 Background: Germline genetic testing is standard of care for treatment planning for several malignancies. To increase access to genetic testing for V...
Video-based genetic counseling to reduce physician workload and enhance consulter understanding: A prospective randomized clinical trial.
1502 Background: Genetic counseling is an essential part of germline genetic testing, which is reccomended for use of PARP inhibitors in breast cancer tre...
Systematic review of immunotherapy-associated cardiotoxicities.
e24005 Background: In recent years, the number of FDA-approved cancer immunotherapy treatments has increased exponentially...
A phase 1 study of fixed-dose regimens of serplulimab, an anti-PD-1 antibody, in patients with advanced solid tumors.
2596 Background: Serplulimab is a recombinant humanized IgG4 monoclonal antibody targeting PD-1. A two-cohort phase 1 study was conducted to evaluate the...
Efficacy and safety of anti-PD-1 combined with thymosin and SOX in neoadjuvant treatment of cStage III gastric or esophagogastric junctional adenocarcinoma (NAPTSOX24): A prospective, open-label, single-arm, phase II clinical study.
e16032 Background: Neoadjuvant immunochemotherapy shows increasing potential in improving resectability and outcomes in gastric cancer, however the clinic...
Association of differential expression of genes with survival and relapse in patients treated on the BILCAP clinical trial: Gene expression identification and response to adjuvant chemotherapy in early-stage biliary tract cancer.
4142 Background: Adjuvant capecitabine is standard of care based on the results of the BILCAP clinical trial, comparing adjuvant capecitabine with observa...
Comparison of outcomes for patients (pts) with R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitor (BTKi) and venetoclax from the TRANSCEND CLL 004 study versus a matched cohort of real-world (RW) pts.
7039 Background: Pts with R/R CLL/SLL who failed BTKi and venetoclax have limited treatment (tx) options and poor prognoses. FDA approval of lisocabtagene...
Pegylated liposomal doxorubicin in advanced, anthracycline pre-treated liposarcoma patients: Report of a single reference center experience.
e23543 Background: Liposarcomas (LPS) encompass a heterogeneous group of soft-tissue sarcomas (SD), including well differentiated/dedifferentiated liposar...